Delivery Order SPE2DB20D3103-SPE2DB25FL5C5

Award Date 10/31/24
Potential Completion Date 11/1/24
Potential Value $7.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $26,428.79, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GEMTESA 75 MG TABLET 90S, a pharmaceutical product, with a completion date of November 1, 2024. This award is a delivery order under an existing Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at...
This federal contract award is a delivery order valued at $10,441.22 issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of GEMTESA 75 MG TABLET 90S, a pharmaceutical product, with a period of performance through May 14, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at...
This federal contract award, valued at $1,327.51, was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GEMTESA 75 MG TABLET 90S, a medical product, with a completion date of November 12, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $14,964.72 firm fixed-price delivery order contract is for the supply of GEMTESA 75 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of November 7, 2024. The award is associated with a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop...
This federal contract award, valued at $7,112.45, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of GEMTESA 75 MG TABLET 90S, a pharmaceutical product, to support federal healthcare programs. The contract has an ultimate completion date of October 29, 2024 and is a firm fixed-price contract type. This award is associated with a larger...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,185.69 firm fixed-price delivery order is for the supply of GEMTESA 75 MG TABLET 90S, a pharmaceutical product, with a period of performance through December 16, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA...
This federal contract award, valued at $7,977.67, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GEMTESA 75 MG TABLET 90S, a pharmaceutical product, with a period of performance through May 21, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,138.89 firm fixed-price delivery order contract is for the supply of GEMTESA 75 MG TABLET 30S, a pharmaceutical product. The contract has a completion date of June 10, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support...
This federal contract award, valued at $52,016.56, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GEMTESA 75 MG TABLET 90S, a medication, with a period of performance through January 21, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical. The IDC...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,865.65, is for the delivery of GEMTESA 75 MG TABLET 90S, a pharmaceutical product, and has a completion date of November 20, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at...
  • SPE2DB20D3103
    Indefinite Delivery Contract
  • SPE2DB20D3103-SPE2DB25FL5C5
    Delivery Order

This federal contract award, valued at $7,326.15, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of GEMTESA 75 MG TABLET 90S, a pharmaceutical product, with an ultimate completion date of November 1, 2024. This contract is a delivery order under an existing Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This contract award does not have a set-aside designation, indicating open competition.

Generated 5/20/25, 1:50 PM